The USP perspective to minimize the potential risk of TSE infectivity in bovine-derived articles used in the manufacture of medical products

Pharmacopeial Forum

Volumn 30, Issue 5, 2004, Pages 1911-1921

  DeVeau, Ian ^a,c   Dabbah, Roger ^a   Sutton, Scott ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b USP Analytical Microbiology Expert Committee

^c UNITED STATES PHARMACOPEIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 25144453756     PISSN: 03634655     EISSN: 15421945     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 9 CFR Part 121.2002. USDA/APHIS: Agricultural Bioterrorism Protection Act of 2002; Possession, Use, and Transfer of Biological Agents and Toxins.
2. Agrimi, U., Ru, G., Cardone, F., Pocchiari, M., and Caramelli, M. 1999. Epidemic of transmissible spongiform encephalopathy in sheep and goats in Italy. Lancet. 353(9152):560-561.
3. APAG (The European Oleochemicals and Allied Products Group). 2003. The safety of tallow derivatives with respect to Bovine Spongiform Encephalopathy-An updated report-August 2003.
4. Bader, R, Davis, G., Dinowitz, M., Garfinkle, B., Harvey, J., Kozak, R., Lubiniecki, A., Rubino, M., Schubert, D., Wiebe, M., and Woolett, G. 1997. Assessment of risk of bovine spongiform encephalopathy in pharmaceutical products. Report of the Pharmaceutical Research and Manufacturers of America BSE Committee. 58 p.
5. Blum, M., Budnick, M., Chait, E., Vaz, W., MacAuley, C., and Rohwer, R. 1998. A bovine spongiform encephalopathy validation study for aprotinin and bovine serum albumin. Biopharm. 11(4):28-33.
6. Bostock, C. 2000. The nature of TSEs. Microbiology Today. 27:164-166.
7. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, Á., Kobayashi, Y., Marino, S., Weissmann, C., and Aguzzi A. 1996. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 379:339-343.
8. Brown, P., Gibbs, C., Rodgers-Johnson, P., Asher, D., Sulima, M., Bacote, A., Goldfarb, L., and Gajdusek, D. 1994. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Annuals of Neurology 35(5):513-529.
9. Brown, P., Will, R., Bradley, R., Asher, D., and Detwiler, L. 2001. Bovine Spongiform Encephalopathy and Variant Creutzfeldt - Jakob disease: Background, evolution, and current concerns. Emerging Infectious Diseases. 7(1):6-16.
10. Bruce, M., Will, R., Ironside, J., McConnell, I., Drummond, D., Suttie, A., McCardle, L., Chree, A., Hope, J., Birkett, C., Cousens, S., Fraser, H., and Bostock C. 1997. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature. 389:498-501.
11. Caramelli, M., Ru, G., Casalone, C., Bozzetta, E. Acutis, P. Calella, A., and Forloni, G. 2001. Evidence for the transmission of scrapie to sheep and goats from a vaccine against Mycoplasma agalactinae. Veterinary Record. 148(17):531-536.
12. Caughey, B. and P.T. Lansbury. 2003. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 26:267-98.
13. CBER (Center for Biologies Evaluation and Research), U.S. Food and Drug Administration. 2000. Letter to Manufacturers of Biological Products.
14. Cervenakova, L., Yakovleva, O., McKenzie, C., Kolchinsky, S., McShane, L., Drohan, W., and Brown P. 2003. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion. 43(12):1687-1694.
15. Cohen, J., Duggar, K., Gray, G., Kreindel, S., Abdelrahman, H., HabteMariam, T., Oryang, D., and Tameru. 2003. Evaluation of the potential for bovine spongiform encephalopathy in the United States. Report of the Harvard Center for Risk Analysis, Harvard School of Public Health/Center for Computational Epidemiology, College of Veterinary Medicine, Tuskegee University: November 26, 2001; revised October 2003. 150 p.
16. Collinge, J., Sidle, K., Meads, J., Ironside, J., and Hill, A. 1996. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature. 383:685-690.
17. Collinge, J. 2001. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Microbiol. 24:519-50
18. Creutzfeldt, H. 1920. Über eine eigenartige herdförmige Enkrankung des Zentralnervensystems. Zeitschrift für die gesamte Neurologie und Psychiatrie. 57:1-18.
19. CVB (Center for Veterinary Biologies). 2001. Notice No. 01-14: Approved Sources of Animal Origin Ingredients; October 5, 2001.
20. DTZ Pieda Consulting. 1998. Economic Impact of the UK economy. A Report commissioned by the UK Agricultural Departments and HM Treasury.
21. EMEA (European Agency for the Evaluation of Medicinal Products), Committee for Proprietary Medicinal Products (CPMP) and Committee for Veterinary Medicinal Products (CVMP). 2001. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products.
22. ES (European Standard). 2000. EN 12442-2:2000 - Animal tissues and their derivatives utilised in the manufacture of medical devices; Part 2: Control on sourcing, collection, and handling.
23. FDA. 1997. Guidance for Industry: "The Sourcing and processing of gelatin to reduce the potential risk posed by bovine spongiform encephalopathy (BSE) in FDA-regulated products for human use." September 1997.
24. Haritani, M., Spencer, Y., and Wells, G. 1994. Hydrated autoclave pretreatment enhancement of prion protein immunoreactivity in formalin-fixed bovine spongiform encephalopathy-affected brain. Acta Neuropathol. 87(1):86-90.
25. Hilton, D., Ghani, A., Conyers, L., Edwards, P., McCardle, L., Ritchie, D., Penney, M., Hegazy, D., and Ironside, J. 2004. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. In press.
26. Hope, J., Wood, S., Birkett, C., Chong, A., Bruce, M., Cairns, D., Goldmann, W, Hunter, N., and Bostock, C. 2002. Molecular analysis of ovine prion protein identifies similarities between BSE and an experimental isolate of natural scrapie, CH1641. J Gen Virol Mar; 81(Pt 3):851.
27. Hunter, N., Foster, J., Chong, A., McCutcheon, S., Parnham, D., Eaton, S., MacKenzie, C., and Houston, F. 2002. Transmission of prion diseases by blood transfusion. J Gen Virol. 83:2897-2905.
28. Inveresk Research International. 1998a. Validation of the clearance of scrapie from the manufacturing process of gelatine. Interim report of the Inveresk Project No. 855028 sponsored by GME Gelatin Manufacturers Europe. Interim Report No. 14682. Tranent, Scotland.
29. Inveresk Research International. 1998b. Validation of the clearance of scrapie from the manufacturing process of gelatine: additional stage. Final report, Inveresk Project No. 855080. Inveresk Report No. 14683. Tranent, Scotland.
30. Inveresk Research International. 1999. Validation of the manufacturing process for gelatine to show reduction of scrapie agent. Inveresk Project No. 856000. Inveresk Report No. 16032. Tranent, Scotland.
31. Ironside, J., Sutherland, K., Bell J., McCardle, L., Barrie, C., Estebeiro, K., Zeidler, M., and Will, R. 1996. A new variant of Creutzfeldt-Jakob disease: Neuropathological and clinical features. Cold Spring Harb Symp Quant Biol. 61:523-530.
32. King, C-Y. and Diaz-Avalos, R. 2004. Protein-only transmission of three yeast prion strains. 428:319-323.
33. Koster, T., Singh, K., Zimmermann, M., and Gruys, E. 2003. Emerging therapeutics agents for transmissible spongiform encephalopathies: A review. Journal of Veterinary Pharmacology and Therapeutics. 26:315-326.
34. Korth, C., Kaneko, K, Groth, D., Heye, N., Telling, G., Mastrianni, J., Parchi, P., Gambetti, P., Will, R., Ironside, J., Heinrich, C., Tremblay, P., DeArmond, S., and Prusiner, S. 2003. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci USA. 100(8):4784-4789.
35. Lindenbaum, S. 2001. Kuru, prions, and human affairs: Thinking about epidemics. Annu Rev Anthropol. 30:363-385.
36. MAFF (Ministry of Agriculture, Fisheries, and Food, UK). 1998. BSE Enforcement Bulletin 27. 24 p.
37. Manuelidis, L. and Lu, Z. 2003. Virus-like interference in the latency and prevention of Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA. 100(9):5360-5365.
38. Marsh, R., Sipe, J., Morse, S., and Hanson, R. 1976. Transmissible mink encephalopathy. Reduced spongiform degeneration in aged mink of the Chediak-Higashi genotype. Lab Invest. 34:381-386.
39. Matthews, D. et al. 2003. BSE: a global update. J of Appl Microbiology. 94:120S-125S.
40. Narang, H. 2002. A critical review of the nature of the spongiform encephalopathy agent: protein theory versus virus theory. Experimental Biology and Medicine 227:4-19.
41. Oesch, B., Doherr, M., Heim, D., Fischer, K., Egli, S., Bolliger, S., Biffiger, K., Schaller, O., Vandevelde, M., and Moser, M. 2000. Application of Prionics Western blotting procedure to screen for BSE in cattle regularly slaughtered at Swiss abattoirs. Arch Virol Suppl 16:189-195.
42. OIE (Office International des Epizootics). 2003. Terrestrial Animal Health Code, Chapter 2.3.13, Bovine Spongiform Encephalopathy. pp. 216-226.
43. OIE (Office International des Epizooties). 2004. Animal disease data: number of reported cases of bovine spongiform encephalopathy (BSE) in the United Kingdom and worldwide (excluding the United Kingdom), www.oie.int.
44. O'Rourke, K., Baszler, T., Besser, T., Miller, J., Cutlip, R., Wells, G., Ryder, S., Parish, S., Hamir, A., Cockett, N., Jenny, A., and Knowles, D. 2000. Preclinical diagnosis of scrapie by immunohistochemistry of third eyelid lymphoid tissue. J Clin Microbiol. 38(9):3254-3259.
45. Pan, K., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., Huang, Z., Fletterick, R., Cohen, F., and Pruisner, S. 1993. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 90(23):10962-10966.
46. Priola, S. Chesebro, B., and Caughey, B. 2003. A view from the top-prion diseases from 10,000 feet. Science. 300:917-919.
47. Prusiner, S. 1991. Molecular biology of prion diseases. Science. 252:1515-1522.
48. Schmerr, M.-J., Jenny, A., Bulgin, M., Miller, J., Hamir, A., Cutlip, R., and Goodwin K. 1999. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A. 853(1-2):207-214.
49. Schmitt, J., Beekes, M., Brauer, A., Udelhoven, T., Lasch, P., and Naumann, D. 2002. Identification of scrapie infection from blood serum by Fourier transform infrared spectroscopy. Anal Chem. 74(15):3865-3868.
50. Schreuder, B., van Keulen, L., Vromans, M., Langeveld, J., and Smits, M. 1998. Tonsillar biopsy and PrPSc detection in the preclinical diagnosis of scrapie. The Veterinary Record. 142(21):564-568.
51. Shaked, G., Shaked, Y., Kariv, Z., Halimi, M., Avraham, I., and Gabizon, R. 2001. A protease resistant PrP isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem. 276(34):31479-31482.
52. Taylor, D., Woodgate, S., and Atkinson, M. 1995. Inactivation of the bovine spongiform encephalopathy agent by rendering procedures. The Veterinary Record. 137:605-610.
53. Terry, L., Marsh, S., Ryder, S., Hawkins, S., Wells, G., and Spencer, Y. 2003. Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy. The Veterinary Record. 152(13):387-392.
54. The Safety of Tallow Derivatives with Respect to Bovine Spongiform Encephalopathy - An Undated Report. 2003. The European Oleochemicals & Allied Products Group, pp. 1-18.
55. SC accumulation in muscles of hamsters orally infected with scrapie. EMBO Rep. 4(5):1-4.
56. Uptain, S.M. and S. Lindquist. 2002. Prions as protein based genetic elements. Annu Rev Microbiol. 56:703-41.
57. USP 27-NF 22. General Chapter (111) Design and Analysis of Biological Assays.
58. Wells, G., Scott, A., Johnson, C., Gunning, R., Hancock, R., Jeffrey, M., Dawson, M., and Bradley, R. 1987. A novel progressive spongiform encephalopathy in cattle. The Veterinary Record 121(18):419-420.
59. WHO. 1999. Report: WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies.
60. Wilesmith, J., Ryan, J., and Atkinson, M. 1991. An Epidemiological examination of the spread and origin of BSE in cattle. The Veterinary Record. 128:199-203.
61. Will, R., Ironside, J., Zeidler, M., Cousens, S., Estibeiro, K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A., and Smith, P. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 347:921-925.
62. Williams, E. and Young, S. 1980. CWD of captive mule deer: A spongiform encephalopathy. Journal of Wildlife Diseases 16:89-98.